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Acquired resistance to second generation BRAF inhibitors (BRAFis), like vemurafenib is limiting the beneﬁts of
long term targeted therapy for patients with malignant melanomas that harbor BRAF V600 mutations. Since
many resistance mechanisms have been described, most of them causing a hyperactivation of the MAPK- or
PI3K/AKT signaling pathways, one potential strategy to overcome BRAFi resistance in melanoma cells would be
to target important common signaling nodes. Known factors that cause secondary resistance include the
overexpression of receptor tyrosine kinases (RTKs), alternative splicing of BRAF or the occurrence of novel
mutations in MEK1 or NRAS.
In this study we show that β-catenin is stabilized and translocated to the nucleus in approximately half of the
melanomas that were analyzed and which developed secondary resistance towards BRAFi. We further
demonstrate that β-catenin is involved in the mediation of resistance towards vemurafenib in vitro and in vivo.
Unexpectedly, β-catenin acts mainly independent of the TCF/LEF dependent canonical Wnt-signaling pathway
in resistance development, which partly explains previous contradictory results about the role of β-catenin in
melanoma progression and therapy resistance. We further demonstrate that β-catenin interacts with Stat3
after chronic vemurafenib treatment and both together cooperate in the acquisition and maintenance of
resistance towards BRAFi.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Approximately 50% of human melanomas harbor activating V600E/
K mutations in the serine/threonine kinase BRAF resulting in constitu-
tive activation of the RAF/MEK/ERK mitogen-activated protein kinase
(MAPK) pathway (Davies et al., 2002; Kumar et al., 2003; Long et al.,
2011). Clinical trials with BRAF inhibitors (BRAFis) such as vemurafenib
and dabrafenib that speciﬁcally target these mutated forms and cause
an effective inhibition of theMAPK pathway have shown impressive re-
sponse rates of N50% in patients with metastatic melanoma harboring
the BRAF V600E mutation (Chapman et al., 2011; Flaherty et al., 2010;
Hauschild et al., 2012) which were conﬁrmed in daily routine in the
clinics. However, the acquisition of secondary resistance leading to re-
lapse within 7–12 months was observed in a majority of patients
(Carlino et al., 2013; Chapman et al., 2012; Menzies and Long, 2014;
Wagle et al., 2011). Analyses of the underlying resistance mechanisms
in these patients indicated that some vemurafenib-resistant melanoma
cells have reactivated the MAPK signaling pathway by alternative
mechanisms (Holderﬁeld et al., 2014) which promoted successful
clinical trials using combinations of BRAF inhibitorswithMEK inhibitors
(Johnson et al., 2014; Long et al., 2014; Robert et al., 2014). However,
although the median progression-free survival in the group receiving
the BRAF and MEK inhibitor was nearly doubled, compared to the
mono-therapy group, resistance still developed. Therefore, additional
factors independent of MAPK reactivation must play a role in resistance
acquisition to BRAFi as well. Indeed, resistance to BRAF or MEK
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inhibitors correlated with the activation of PI3K/AKT signaling pathway
which is achieved by up-regulation of receptor tyrosine kinases (RTKs)
such as platelet-derived growth factor receptor (PDGFR) beta, vascular
endothelial growth factor receptor (VEGFR), epidermal growth factor
receptor (EGFR), insulin-growth factor receptor 1 (IGF1R) and thehepa-
tocyte growth factor (HGF) receptor c-met (Girotti et al., 2013; Nazarian
et al., 2010; Straussman et al., 2012; Sun et al., 2014; Villanueva et al.,
2010; Wilson et al., 2012). However, the available data suggest that
multiple RTKs are up-regulated or hyper-activated in therapy-
resistant cells and that targeting of only oneRTK is not sufﬁcient to over-
come therapy resistance in general. Since RTKs activate both, theMAPK
and PI3K/AKT signaling pathways, a potential strategy to overcome re-
sistance to BRAFi in melanoma cells would be to target common impor-
tant signaling nodes rather than attempting to target a speciﬁc RTK.
One key nodal point is β-catenin, which acts as a transcriptional
activator in many signaling pathways, including the Wnt, EGF (Ji et al.,
2009), HGF (Purcell et al., 2011), IGF (Desbois-Mouthon et al., 2001),
TGF (Zhou, 2011) and cadherin pathways (Benham-Pyle et al., 2015;
Zhang et al., 2013). Beta-catenin regulates the expression of several
genes involved in tumor progression and is part of at least three major
functional distinct complexes in a cell. First, β-catenin is a component
of adherens junctions where it links cadherins to the cytoskeleton.
Second, a cytoplasmic complex regulates its degradation by the
interaction with casein kinase 1α (CK1α), glycogen synthase kinase 3
(GSK3), adenomatous polyposis coli (APC) and axin-1. Third, β-
catenin accumulates upon activation and translocates to the nucleus,
where it classically transactivates transcription of β-catenin/T cell
factor/lymphocyte enhancer binding factor (TCF/LEF)-responsive
genes together with TCF/LEF family members (Watanabe and Dai,
2011).
The role of theβ-catenin signalingpathway in therapy resistancehas
been sparsely analyzed so far. Beta-catenin signaling is involved in AKT
activation in prostate cancer cells, whereas inhibition down-regulates
AKT activity and induces chemosensitivity in PTEN-mutated prostate
cancer cells. Activation of β-catenin signaling mediates chemo-
resistance in several solid tumors (Saifo et al., 2010). It is further specu-
lated that increased chemoresistance is partially linked to β-catenin-
mediated up-regulation of drug efﬂux transporters like MDR-1 (Lim
et al., 2009). In therapy-resistant colorectal cancer cells, expression of
the transcription factor TCF4was found to be up-regulated and silencing
of TCF4 sensitized the cells to chemo- and radiotherapy (Kendziorra
et al., 2011). Our own data indicate that β-catenin plays a critical role
in chemoresistance of melanoma cells (Sinnberg et al., 2011). In con-
trast, it was shown that vemurafenib treated A375 melanoma cells
have activated β-catenin signaling which in turn synergized with
vemurafenib to induce apoptosis (Biechele et al., 2012). Moreover the
studies of Biechele and Conrad revealed an additional important role
of β-catenin in the induction of apoptosis after MEK inhibition
provoking a pro-apoptotic role of β-catenin in the course ofMAPK path-
way inhibition (Conrad et al., 2012). However, the same group recently
published that elevated nuclear β-catenin levels correlated with a
worse prognosis for BRAFi treatedmelanoma patients,which developed
secondary resistance in their tumors (Chien et al., 2014). These contra-
dictory results indicate an urgent need to unravel the role of β-catenin
in the mechanisms mediating acquired therapy resistance towards
BRAFi.
2. Materials and Methods
2.1. Cell Culture of Melanoma Cell Lines
The human metastatic BRAFV600E mutated melanoma cell lines
451Lu, Mel1617, A375, and SKMel19were cultured in RPMI 1640Medi-
um (Gibco life technologies) which was supplemented with 10% fetal
calf serum (FCS) (Biochrom/Merck Millipore,) and 1% Penicillin and
Streptomycin (Gibco/life technologies). The vemurafenib resistant cell
lines were generated by continuous treatment with increasing concen-
tration of PLX4032 up to 2 μM for several months. The culture medium
of the resistant cell lines was changed to a PLX4032 free medium 24 h
before they were subjected into experiments.
The 451Lu cells stably expressing tetracycline-inducible shRNA
against β-catenin (451Lu TetOn-shCTNNB1) were generated as
previously described (Sinnberg et al., 2011). The shRNA against β-
catenin was induced by the application of 1 μg/ml doxycycline to the
culturemedium for 24 h to 96 h before theywere used in the respective
experiments.
2.2. Chemicals
The BRAFV600E/K kinase inhibitor PLX4032 vemurafenib (LC Labo-
ratories), Stat3 inhibitors Stattic and S3I-201 (both Selleck) as well as
the β-catenin/TCF complex inhibitor PKF-115-584 (Novartis) were
used for the speciﬁc inhibition of signaling pathways. For Tet-
inducible shRNA induction doxycycline (Applichem) was used. Wnt3A
and Wnt5A (StemRD) were used for the activation of Wnt signaling.
2.3. Viability assays
4-Methylumbelliferyl heptanoate (MUH) assay was performed for
the analysis of the cell viability. 2.5 × 103 cells were seeded into 96
well plate cavities in quintuplicates or sixtuplicates 24 h before
treatment. According to the analysis, cells were pre-stimulated with
PKF-115-564 (50 ng/ml), with lithium chloride (7.5 mM), with Wnt3A
or Wnt5A (up to 100 ng/ml) for 6 h as well as with Stattic (up to
6 μM) or S31–201 (up to 160 μM) for 3 h. Additionally the cells were
treated with PLX4032 (up to 20 μM) for 72 h. Viability analysis was
performed after a washing step using PBS and subsequent incubation
of the cells in 100 μg/ml 4-methylumbelliferyl heptanoate diluted in
PBS for 1 h at 37 °C. The ﬂuorescence (ex355nm/em460nm) was
detected in a Tristar ﬂuorescence microplate reader (Berthold).
Alamar blue viability assay was used to analyze the viability of
transfected cells for normalizing reporter assay signals to cellular
viability when no Renilla-CMV was used. Brieﬂy 1 mg/ml alamar blue
stock solution was pre-diluted in culture medium (1:10) and 10 μl of
this solutionwas added to 100 μl culturemediumof each 96well cavity.
After incubation for 1 h at 37 °C the ﬂuorescence of resofurin was
measured in ﬂuorescence microplate reader (Berthold, Germany) at
ex540nm/em640nm. Background subtracted sample values were used
for normalization of reporter signals.
2.4. Luciferase Reporter Assays
SuperTopFlash, pcDNA3.1-GLuci-CRE/-AP1/-NFAT as well as
pLucTKS3 (Stat3) reporter were transiently transfected for the analysis
of speciﬁc pathway activity. 2.5 × 105 melanoma cells were seeded
into 6 well plate cavities 24 h prior to transfection. Reporter plasmids
(2 μg/well) and CMV renilla plasmids (120 ng/well) were co-
transfected using ScreenFect A Transfection Kits (Genaxxon bioscience)
or Lipofectamine 3000 Transfection Reagent (Life Technologies) accord-
ing to the manufacturer's protocols for 24 h. Then 1 × 104 transfected
cells were seeded into 96 well plate cavities at minimum in quintupli-
cates and optionally pre-treated with 15 mM lithium chloride for 6 h.
Additional treatments were PLX4032 (up to 10 μM), Stattic (up to
2 μM) or Wnt5a and Wnt3a (100 ng/ml) for further 24 h. Cells were
lysed in 50 μl passive lysis buffer (Promega). 10 μl of lysates or 10 μl of
supernatant of the culture medium (Gaussia reporters) was used for
the measurement of the ﬁreﬂy and renilla luciferase activity in a Tristar
luminometer (Berthold). Luciferase activity was measured using D-
luciferin or renilla and gaussia substrate coelentarazine as previously
described (Albert and Silvia, 2012).
133T. Sinnberg et al. / EBioMedicine 8 (2016) 132–149
2.5. Cell Cycle Assay
2 × 105 melanoma cells per 6 well cavity were seeded 24 h prior to
treatment. DMSO (0.02–0.05%) treated control cells and PLX4032 (2
or 5 μM) treated cells were analyzed in triplicates. Cells were commonly
treated for 72 h. After permeabilization of the cells in 70% ice-cold
ethanol for at least 1 h, they were re-suspended in PBS with 100 μg/ml
RNAseA (Applichem) and 50 μg/ml propidium iodide (Sigma) and
stained for 30 min. FACS analysis for the detection of the distribution
of the cells in the each cell cycle phases was performed with a LSRII
FACS (BD) using FACSDiva software (BD).
2.6. SA-Beta-Galactosidase Staining
The Senescence Cells Histochemical Staining Kit (Sigma-Aldrich)
was used according to the manufacturer's recommendations. Brieﬂy,
1.0 × 105 cells were seeded into 12 well plates and treated with the
indicated concentrations of vemurafenib for 72 h. In case of co-
Fig. 1. Beta-catenin expression levels increase in BRAFi resistantmelanomas cells compared to the sensitive parentals. a) Immunohistochemical staining forβ-catenin of clinical specimens
before and after the acquisition of resistance to BRAFi. Beta-catenin expression levels are shown in red (Fast Red substrate) with hematoxylin counter staining (scale bar is 100 μm). b)
Immunoblots of whole cell lysates from sensitive and resistant pairs of the melanoma cell lines 451Lu, Mel1617, A375 and SKMel19 showing the expression levels of β-catenin and
(phospho) Erk1/2. Semiquantitative analysis was performed by building the ratios of (β-catenin:β-actin) and (p-ERk1/2:Erk1/2) and normalization to the sensitive cells.
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treatmentwith doxycycline for the induction of shRNA, a pre-treatment
with 1 μg/ml doxycycline for 24 h was performed. After ﬁxation and
washing of the cells theywere stained using the x-gal substrate solution
for approx. 3 h at 37 °C without CO2. The percentage of senescent cells
was calculated using the ratio of blue cells to total cell number per
microscopic picture. Three independent samples were analyzed in
quadruplicates.
2.7. Immunohistochemistry
For immunoﬂuorescence staining of cultivated cells, 2.5 × 104 cells
were seeded per chamber on 8 well chamber slides (BD Falcon) and
grown for 24 h. The cells were treated with 0.02% DMSO or 2 μM
PLX4032 for 24 h, washed with PBS and ﬁxed in 4% formaldehyde for
15 min. They were blocked in PBS/1%BSA/0.3% Triton-X100 and
incubated overnight with the primary antibody against β-catenin
(1:100 dilutions, Cell Signaling #9562). For the detection, the samples
were incubated with the secondary antibody Alexa Fluor® 647-
conjugated AfﬁniPure Fab Fragment Donkey anti-Rabbit IgG(H + L)
(Jackson ImmunoReserarch) for 2 h. The nuclear staining was per-
formed by monomeric cyanine nucleic acid stain (YO-PRO-1)
(Invitrogen). Immunohistochemistry staining of clinical FFPE specimens
was performed with a β-catenin speciﬁc antibody (Cell Signaling
#9562) diluted 1:50 in PBS containing 0.3% Triton-X100 and 1% BSA.
Brieﬂy 5 μm FFPE tissue sections were de-parafﬁnized and antigen re-
trieval was performed in citrate buffer pH 6 in a pressure cooker for
2 min under pressure before a slow cooling down of the samples in
the hot buffer. Afterwards tissue sections were stained according to
the manufacturer's protocol (Thermo Scientiﬁc Lab Vision UltraVision
LP Detection System: AP Polymer) using FastRed (Thermo Scientiﬁc
Lab Vision Liquid Fast-Red Substrate System) as substrate.
2.8. Western Blotting
Melanoma cells were harvested with Trypsin/EDTA (Biochrom/
Merck Millipore,), washed two times with cold PBS and lysed in RIPA
Fig. 2. Nuclear localized beta-catenin in BRAFi resistant melanomas cells compared to the sensitive parentals. a) Immunoﬂuorescence staining for β-catenin (blue) and nuclear YOPRO-1
staining (green) with confocal microscopy for expression and localization analysis of β-catenin (white scale bars represent 50 μm). b) Immunoblot of cytosolic and nuclear extracts
showing the increased nuclear localization of β-catenin in the resistant cells of the cell lines 451Lu, Mel1617 and A375. Semiquantitation was performed densitometrically by using
the ratios of [β-catenin:β-actin] for cytosolic and [β-catenin:LaminB] for nuclear fractions of the sensitive and resistant cell line pairs. All ratios were normalized to the sensitive
parental cell line to compare the sensitive to the corresponding resistant cell line.
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Lysis Buffer (Thermo Scientiﬁc). For preparation of nuclear and cyto-
plasmic protein extracts NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Thermo Scientiﬁc) were used according to the
manufacturer's protocol. 15 μg of whole cell lysate protein samples or
cytoplasmic protein samples as well as 5 μg of nuclear fraction protein
samples were used for the SDS-PAGE followed by blotting onto PVDF
membranes (Roche). After blocking for 60 min in PBS-T (0.1% Tween-
20) with 5% dry milk the following primary antibodies were applied
on a roller mixer overnight: phospho-Stat3 (Ser727), phospho-Stat3
(Tyr705), Stat3 (79D7), Stat3 (124H6), β-actin (D6A8), β-catenin
(D10A8), phospho-p42/44 MAPK (ERK1/2), p42/44 MAPK (ERK1/2),
LEF1 (C12A5), TCF4 (C48H11), phospho-AKT (Ser473), AKT, phospho-
GSK-3β (Ser9) (D85E12), GSK-3β (D5C5Z), Wnt5a/b (C27E8), GAPDH
(14C10) (all Cell Signaling Technology); β-catenin E-5 (sc-7963),
lamin-B (sc-6216) (Santa Cruz Biotechnology); MITF (C5) (Cat.No.
OP126L) (Calbiochem.). Immunodetection was performed using anti-
rabbit or anti-mouse secondary peroxidase-conjugated antibodies
(Cell Signaling Technology). Visualization was done with using ECL
(Thermo) or ECL prime (GE Helathcare Lifesciences). Anti-rabbit (Cell
Signaling Technology) and anti-goat (Novus) AP conjugated antibodies
were used as well. In these cases detection was performed with CDP-
Star (Roche) according to the manual.
2.9. Miniaturized GST-Pulldown-Assay for the Quantiﬁcation of “Free” β-
Catenin
The quantity of the “free” β-catenin pool which is involved in the
Wnt/β-catenin signaling was determined using a miniaturized bead-
based GST-pulldown assay as described previously (Luckert et al.,
2012). Total β-catenin wasmeasured using a bead-based sandwich im-
munoassay for normalization. The analyses were performed with 20 μg
protein extract derived from sensitive and resistant melanoma cell cul-
tures. Results have been normalized by forming the average of total β-
catenin and “free” β-catenin.
2.10. Co-immunoprecipitation
Cell pellets were homogenized in 200 μl lysis buffer (10 mM Tris/
Cl pH7.5, 150 mM NaCl, 0.5% NP40, 1 μg DNaseI, 2 mM MgCl2, 2 mM
PMSF, 1× phosSTOP phosphatase inhibitor (Roche), 1× protease
inhibitor mix M (Serva) by repeated pipetting for 40 min on ice.
After a centrifugation step (10 min at 18,000 ×g) the soluble protein
fraction was incubated with 50 μl of the agarose-coupled BC2-
nanobody (Traenkle et al., 2015) for 12 h on an end-over-end rotor
at 4 °C. The bead pellet was washed two times in 0.5 ml dilution buff-
er (10 mM Tris/Cl pH 7.5, 150 mM NaCl, 2 mM PMSF). After the last
washing step the beads were transferred to a new cup, resuspended
in 2× SDS-containing sample buffer and boiled for 10 min at 95 °C.
Samples (5% input, 5% non-bound and 10% bound) were analyzed
by SDS-PAGE followed by western blotting. Immunoblots were
probed with antibodies directed against β-catenin, GAPDH, MITF,
and LEF-1.
For the detection of the interaction with Stat3, proteins were cross-
linked using 0.4% formaldehyde/PBS solution before the precipitation.
5 × 106 cells were resuspended in 2 ml ﬁxing solution and incubated
at room temperature for 4 min on a roller mixer before centrifugation
at 320 ×g for 3 min. The supernatants were removed and the cells
were incubated in 1ml ice-cold 1.25M glycine/PBS for 1 min to quench
the formalin reaction and were centrifuged for 3 min. The cells were
washed in 5 ml PBS and lysed in 250 μl RIPA-Buffer (Thermo Scientiﬁc)
for 60 min. The precipitation was performed according to the co-
immunoprecipitation protocol (Cell Signaling). The proteins were
precipitated using β-catenin (D10A) XP Rabbit (Cell Signaling
Technology), β-catenin (E-5) sc-7963 mouse antibody (Santa Cruz
Technology), Stat3 (D3Z2G) Rabbit mAb and Stat3 (124H6) Mouse
mAb (both Cell Signaling Biotechnology) and the bound proteins were
detected.
2.11. siRNA Transfection
20 nM siRNA (all synthesized by biomers.net Germany) against
Stat3 (sense: aacuucagacccgucaacaaa-dTdT;; antisense: uuuguugacggg
ucugaag-dTdT) and β-catenin (sense: gguggugguuaauaaggcu-dTdT; an-
tisense: agccuuauuaaccaccacc-dTdG) were reversely transfected using
the riboxx FECT (riboxx Life Sciences) on 96 well plates. Therefore, the
riboxxFECT (1:25) and siRNA were separately diluted using Opti-MEM
(Life technologies) and the solutions were gently mixed in a 1:1 ratio.
The solutionwas incubated for 15min and subsequently, 50 μl of the so-
lution was transferred to each 96-well cavities. Additionally, 2.5 × 103
cells resuspended in 50 μl culture medium were added to each well
and incubated for 24 h at 37 °C. The transfected cells were subsequently
treated with up to 20 μM PLX4032 for 72 h and the viability was mea-
sured viaMUH assay.
2.12. Lentiviral Gene Transfer
Stat3 overexpression lentivirus was produced using HEK 293T cells
(Biocat, Germany) transfected with human STAT3 cloned into pLX304
(HsCD00443857 DNASU plasmid repository (Seiler et al., 2013)) as
well as second-generation packaging and envelope plasmids
pCMVΔR8.2 and pMD2.G. Melanoma cells were transduced with lenti-
virus containing supernatants in the presence of 8 μg/ml polybrene
(Sigma) and cultured in 5 μg/ml blasticidin (Merck Millipore) contain-
ing selection medium.
2.13. Xenograft Melanoma Model
For the in vivo tumor growth assays, 1 × 106 vemurafenib resistant
451Lu cells stably expressing tetracycline-inducible shRNA against β-
catenin were subcutaneously injected into SCID mice. All mice were
daily treated with 25 mg/kg vemurafenib (LC Laboratories) i.p. for
25 days post injection, until they developed approx. 100 mm3 tumor
nodules. The mice were randomized into four groups (n = 5). The
ﬁrst group was subsequently fed with 1 mg/ml doxycycline
(Applichem) in the drinking water, the second group received daily
injections of 25 mg/kg vemurafenib i.p, the third group received both
treatments and the fourth group served as untreated control group.
Drinking water was generally supplemented with 1% sucrose to reduce
the bitter taste due to doxycycline. The Tumor size was monitored for
40 days post injection by calliper measurements of tumor length and
Fig. 3. Beta-catenin is directly involved in the efﬁcacy of the response to BRAFi and suppresses growth inhibition a) Cell viability assay (MUH) of melanoma cell lines pre-treated with
7.5 mM LiCl for 24 h for stabilization of β-catenin. Immunoblots show the stabilization of β-catenin after treatment of 451Lu cells with LiCl. After the pre-treatment, cells were treated
with increasing concentrations of vemurafenib for 72 h before the assessment of cell viability. Black symbols represent sensitive control cells and red symbols represent LiCl pre-
treated cells. Signals were normalized to the control cells without vemurafenib treatment. Mean +/ SD values of six replicates are shown. Multiple t-tests with Holm–Šídák correction
were used to compare data points of the two curves and p b 0.05 was considered as signiﬁcant (asterisk). b) Cell viability assays (MUH) after Tet-inducible knockdown of β-catenin in
451LuTet-S (left diagram) or 451LuTet-R cells (right diagram). Knockdown was induced by pre-treatment with 1 μg/ml doxycycline for 24 h (red symbols) and compared to cells
without doxycycline treatment (black symbols). Multiple t-tests with Holm–Šídák correction were used to compare data points of the two curves and p b 0.05 was considered as
signiﬁcant (asterisk). F-test revealed a signiﬁcant different IC50 of the ﬁtted curves. c) Immunoblot analysis for β-catenin and (phospho-) Erk1/2 shows protein level changes after
induction of shCTNNB1 in combination with vemurafenib treatment 24 h after treatment in comparison to vehicle control treated cells.
136 T. Sinnberg et al. / EBioMedicine 8 (2016) 132–149
width. The tumor volume was calculated using the following formula:
V = 0.4 × length × width2. All animal experiments were approved
by the regional council (Regierungspraesidium Tuebingen Az35/
9185.81-2).
2.14. PET Imaging
Animals were fasted for 6 h prior to the FDG injection and doxycy-
cline treatment was interrupted due to the necessary sucrose addition
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to the drinking water. ~13 MBq FDG in a max. volume of 100 μl were
injected i.v. into the tail vein under 1.5% isoﬂurane narcosis evaporated
in oxygen at a ﬂow rate of 0.5 l/min (Abbott, Wiesbaden, Germany) and
the animals were kept under anesthesia for 55 min. post-injection in a
heated box. Blood glucose and body weight measurements were
performed immediately before FDG injection. Subsequently animals
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were placed on a carbon bed and scanned for 10min in an Inveon small
animal PET scanner (Siemens Preclinical Solutions, Knoxville, TN, USA).
Body temperaturewasmaintained at 37 °C by a heating pad and a rectal
temperature sensor. Image reconstruction was performed using
Inveon Acquisition Workplace 1.5.0.28 (Siemens Preclinical Solutions,
Knoxville, TN, USA) with an iterative ordered-subset expectation
maximization algorithm (OSEM2D)with four iterations. No attenuation
and scatter correction was applied, according to our standard protocol
for PET imaging with mice. The reconstructed voxel size was
0.776 × 0.776 × 0.796 mm. Images were analyzed in Inveon Research
Workplace (Siemens Preclinical Solutions, Knoxville, TN, USA).
2.15. Statistical Analysis
Microsoft Excel and Graphpad Prism 6.0 were used for the statistical
analyses of the data. Graphs show mean values with their SD unless
differently mentioned. Statistic used for p-value calculations and
signiﬁcance determinations are given in the corresponding ﬁgure
legends. p-values b 0.05 were considered statistically signiﬁcant (with
* for p b 0.05, ** for p b 0.01 and *** for p b 0.001). Dose response curves
were ﬁtted using Graphpad Prism6.0 for IC50 calculations (usingmostly
the nonlinear regression curve ﬁt log(inhibitor) vs. response with
variable slope).
Fig. 5. Knockdown of β-catenin synergizeswith vemurafenib for the inhibition of tumor growth of BRAFi resistantmelanomas. a) Xenograft experiment using Tet-inducible 451Lu-R cells
for s.c. injection (1 × 106 cells) into SHO mice. After formation of 100 mm3 tumor nodules upon daily i.p. injections with vemurafenib (25 mg/kg) the mice were randomized into four
treatment groups: i) vemurafenib treatment (black), ii) untreated (grey), iii) shRNA induction by doxycycline (1 mg/ml) in the drinking water ad libitum and (green) iv) combination
(red) (n = 5 per group). The tumor growth was daily monitored by caliper measurements and normalized to the size at day 0 of treatment. Multiple t tests were used to determine
the data points of the combination group with p b 0.05 (asterisk). b) Positron emission tomography using F18-FDG was performed on days 4, 8 and 12 post-start of therapy. c)
Immunistochemistry of removed tumors from SHO mice (from 2F). Tumors of every group were stained for β-catenin expression, phospho-Erk1/2 and Ki67 using Fast Red as
substrate. Representative microscopic pictures are shown of every group (scale bars indicate 100 μm). d) Ki67 positive cells were counted and normalized to total cell numbers as
indicator for cell proliferation. Three different tumors per group were used for data analysis. Mean percentages +/− SD are shown. ANOVA analysis was performed using Tukey's
multiple comparisons test (asterisks).
Fig. 4. Knockdown of β-catenin enhances the BRAFi mediated induction of apoptosis and senescence. a) Cell cycle analysis of Tet-inducible 451LuTet-S (upper panel) and 451LuTet-R
(lower panel) cells after treatment with 5 or 10 μM vemurafenib for 72 h. Doxycycline pre-treatment for 24 h (right bar diagrams) was used to induce β-catenin speciﬁc shRNA.
Representative FACS histograms of the cell cycle analysis comparing vehicle (DMSO) treated cells with vemurafenib (10 μM) are shown. Cell cycle distributions represent the result of
three biologic replicates (mean +/− SD). b) SA-associated β-galactosidase staining after 72 h of vemurafenib treatment of the above mentioned Tet-inducible cells (scale bars
represent 200 μm). Clear blue cells were counted and normalized to the total number of cells using four different microscopic pictures (top row) per treatment. Mean numbers +/−
SD are shown from three independent biological replicates (bottom row). ANOVA analyis was performed using Tukey's multiple comparisons test (asterisks).
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3. Results
3.1. A Subset of Vemurafenib Resistant Melanoma Cells Exhibit Stabilized
Nuclear β-Catenin In Vivo and In Vitro
In our previous work we found elevated levels of nuclear β-catenin
in several metastatic melanoma biopsies and cell lines compared to
cell lines of radial growth phase origin (Sinnberg et al., 2010, 2011).
To investigate whether β-catenin levels are also altered during resis-
tance development to BRAFi treatment, we collected tumor biopsies
from eight stage IV melanoma patients before initiation of vemurafenib
treatment and after development of drug resistance for analysis of β-
catenin protein expression by immunohistochemistry. Time to resis-
tance development in the presented cases was 5 to 12 months
(Fig. 1a). We observed accumulation of β-catenin in 4 out of 8
resistance-acquired tumors (50%) in comparison to the β-catenin levels
in excised lesions collected before the start of the treatment (Fig. 1a). In
one sample pair (12.5%) a diverse expression pattern was seen includ-
ing areas with increased β-catenin levels, whereas in three samples no
increase in β-catenin expressionwas detected (37.5%).We used a tissue
microarray to compare the observed frequencies of strong β-catenin
staining with BRAFi naïve melanomas (Supplementary Fig. 1). Among
the 270 primary melanomas 39 showed strong β-catenin expression
(14.5%) and 203 amoderate staining (60.7%). None of the 13metastatic
melanomas had a strong signal intensity (0%) and seven biopsies
showed a moderate (53.8%) staining pattern. This clearly shows that
the high expression level of β-catenin in 50% of the BRAFi resistant
tumor biopsies is extraordinary.
To unravel the functional relevance of β-catenin expression on
BRAFi resistance development we generated BRAFi resistant melanoma
cell lines (Mel1617-R, 451Lu-R, A375-R, and SKMel19-R) by continuous
treatment with vemurafenib. The chronically treated cells were signiﬁ-
cantly more resistant to BRAF inhibition with less affected cellular via-
bility and reduced apoptosis induction compared to the respective
parental sensitive cell lines (Mel1617-S, 451Lu-S, A375-S, and
SKMel19-S) (Supplementary Fig. 2a, b). On a molecular level the resis-
tant cell lines showed a strong MAPK pathway activity based on high
phosphorylation of Erk1/2 (Fig. 1b). Phospho-AKT was moderately in-
creased in resistant Mel1617 and A375 cells (Supplementary Fig. 1f).
We tested for different resistance mechanisms that lead to the re- and
hyperactivation of the MAPK signaling pathway. No novel mutations
in NRAS (codon 61) or MEK1 (exons 2, 3 and 6) could be detected by
Sanger sequencing in the resistant cell lines (Supplementary Fig. 1c). In-
terestingly A375-R and SKMel19-R cells showed signs of highly
enriched truncated BRAF (t-BRAF) splice products which are known to
be associated with BRAFi adaptation and resistance mediation (Supple-
mentary Fig. 1d). We further analyzed the expression of several RTKs
(KIT, PDGFRB, MET, IGF1R, EGFR), the alternative MEK activator COT
and BRAF (Supplementary Fig. 1e) on a transcriptional level. PDGFRB
and EGFR mRNA levels were upregulated especially in 451Lu-R cells
whereas SKMel19-R had higher levels of mRNA coding for MET. Total
β-catenin protein levels were at similar levels or only modestly
increased in Mel1617-R and 451Lu-R cells and even decreased in
SKMel19-R cells. We found no consistent change in the expression of
components of other signaling pathways like PTEN in cellular lysates
of resistant cells compared to their sensitive counterparts (Supplemen-
tary Fig. 1f) pointing to the diversity of resistance mechanisms in our
cell lines. Immunoﬂuorescence staining and confocal microscopy indi-
cated a prominent nuclear localization of β-catenin in vemurafenib re-
sistant melanoma Mel1617-R, 451Lu-R and A375-R cells in
comparison to the sensitive parental cells (Fig. 2a). Further western
blot analyses of fractionated cell lysates conﬁrmed that the resistance-
acquired cell lines 451Lu-R, Mel1617-R and A375-R exhibit increased
nuclear β-catenin levels (Fig. 2b). We further analyzed the protein ex-
pression of important β-catenin regulating proteins (Axin1, APC,
sFRP1) in order to ﬁnd the trigger of β-catenin up-regulation and nucle-
ar translocation. No consistent changes were detected and resistant
cells expressed rather high levels of APC, a component of the cytoplas-
mic degradation complex of β-catenin. SKMel19-R cells produced in-
creased amounts of sFRP1 (Supplementary Fig. 1g). Taken together,
these results indicate that a major subset of vemurafenib resistant mel-
anoma cells with high MAPK signaling activity shows increased nuclear
β-catenin levels in vitro and in vivo.
3.2. β-Catenin Knockdown Sensitizes Melanoma Cells Towards
Vemurafenib Treatment In Vitro and In Vivo
In the next step, we analyzed whether β-catenin is functionally in-
volved in the resistance mechanisms to BRAF inhibitors. Therefore, we
modulated cellular β-catenin levels in different ways in order to test
any β-catenin dependent inﬂuence on the resistance towards
vemurafenib. At ﬁrst, we stabilized β-catenin by the inhibition of
GSK3β using lithium chloride in 451Lu-S, Mel1617-S and A375-S cells.
As expected lithium treatment resulted in an increased phosphorylation
of GSK3β at serine 9 and accumulation of β-catenin. This went along
with an attenuation of the growth inhibitory effect of vemurafenib in
BRAFi-sensitive cells in a mild but signiﬁcant manner (Fig. 3a).
To directly address the effects of β-catenin on resistance to BRAF in-
hibition, we generated vemurafenib resistant 451Lu cells that had been
stably transfectedwith a doxycycline inducible andβ-catenin (CTNNB1)
speciﬁc shRNA vector pTER-shCTNNB1 (Sinnberg et al., 2011; van de
Wetering et al., 2003) before initiation of long-term treatment with
vemurafenib for the development of resistance to BRAFi. The time
until vemurafenib-dependent growth inhibition was overridden by re-
sistance mechanisms was doubled to 8 weeks (compared to almost
4 weeks without induction β-catenin speciﬁc shRNA) if the chronic
BRAFi therapy was combined with permanent knockdown of β-
catenin by the addition of 1 μg/ml doxycycline (Supplementary
Fig. 3a). Treating of the cells with doxycycline resulted in a marked
reduced β-catenin protein level in the parental sensitive as well as in
the 451Lu Tet-inducible cells with acquired resistance to vemurafenib.
Interestingly, the induced β-catenin knockdown signiﬁcantly increased
the susceptibility of the parental sensitive 451Lu cells towards
vemurafenib in the MUH viability assay and cell cycle analysis
Fig. 6. Accumulated β-catenin in BRAFi resistant melanoma cell lines acts independent of the canonical Wnt signaling pathway and the TCF/LEF factors. a) TOPﬂash luciferase reporter
assays were done to measure the transcriptional activity of TCF/LEF complexes. Sensitive (black bars) and resistant (red bars) melanoma cell lines were transfected with the reporter
construct plus CMV-renilla luciferase as a normalization control and treated for 24 h with the indicated concentrations of vemurafenib. For the induction of the full signaling activity a
pre-treatment with 15 mM LiCl was performed. Fireﬂy luciferase activity was normalized to renilla activity. Mean values and standard deviations of six samples are presented.
Multiple t-tests with Holm–Šídák correction were used to compare data of sensitive and resistant samples and p b 0.05 was considered as signiﬁcant (asterisk). b) Co-
immunoprecipitation experiments for the detection of interactions of β-catenin with TCF4, LEF1 and Mitf. Soluble lysates were prepared from the indicated sensitive and resistant
melanoma cells and incubated with an immobilized β-catenin speciﬁc nanobody. Input, non-bound and bound fractions were separated on a SDS-PAGE followed by immunoblot
analysis for the transcription factors TCF4, LEF1 and MITF. c) Cell viability assay (MUH) for testing the effects of released β-catenin from the complexes with TCF/LEF by 50 nM
PKF115–584 (circles with dashed curve). The inhibitor was pre-incubated for 6 h before the treatment with increasing concentrations of vemurafenib for 72 h. The assay was
measured in quintuplicates. Mean values +/− SD are shown. Multiple t-tests with Holm–Šídák correction were used to compare data points of the two curves and p b 0.05 was
considered as signiﬁcant (asterisk). d) TOPFlash assay was used to investigate the inﬂuence of vemurafenib on β-catenin /TCF/LEF dependent transcription. Reporter transfected cells
were treated for 24 h with the indicated concentrations of vemurafenib before assaying the luciferase activity. Fireﬂy values were normalized to renilla signals and to the
corresponding untreated controls. Mean values and standard deviations of sixtuplicates are presented. Multiple t-tests with Holm–Šídák correction were used to compare data of
sensitive and resistant samples and p b 0.05 was considered as signiﬁcant (asterisk).
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(Figs. 3b, 4a). The decreased viability went along with an enhanced
caspase 3/7 activity 48 h after combined knockdown with vemurafenib
treatment. Apoptosis induction was inhibited by pre-treatment of the
cells with 7.5 mM LiCl as β-catenin stabilizing agent (Supplementary
Fig. 3b).
Furthermore, the doxycycline-induced knockdown of β-catenin
even partially re-sensitized the previously insusceptible 451Lu
resistant melanoma cells in terms of reduction of viability and
induction of apoptosis (Fig. 3b, 4a). Diminished phospho-Erk1/2 levels
co-occurred with the knockdown of β-catenin (Fig. 3c) resulting in
markedly reduced cell proliferation and growth arrest,whichwasmain-
ly mediated by a cell cycle arrest in G1 and the induction of senescence
as determined by increased SA-β-galactosidase activity (Fig. 4a, b). In
order to exclude any sensitizing effect of doxycycline on the susceptibil-
ity of BRAFV600E melanoma cells to BRAFi we combined the
vemurafenib treatment with 2 μg/ml doxycycline for three consecutive
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days and could not see any signiﬁcant difference between the mono-
therapy using vemurafenib in ascending concentrations and its combi-
nation with the antibiotic in the viability assay (Supplementary
Fig. 3c). These data indicate that β-catenin is involved in the develop-
ment as well as the maintenance of resistance towards vemurafenib.
Subsequently, we evaluated whether the observed impact of β-
catenin on the efﬁcacy of BRAFis in terms of growth inhibition in vitro
is also a relevant phenomenonunder in vivo conditions. For this purpose
resistant 451Lu cells harboring the Tet-inducible CTNNB1-speciﬁc
shRNA were subcutaneously injected into SHO mice (Fig. 5). The
mice received daily intraperitoneal (i.p.) injections of vemurafenib
(25 mg/kg) for 24 days until a median tumor volume of approximately
100 mm3 was reached. Mice were randomized into four different ther-
apy groups: the 1st group was continued with daily injections of
vemurafenib (i.p. 25 mg/kg), the 2nd group received drinking water
supplemented with doxycycline (1 mg/ml), the 3rd group was treated
with a combination of vemurafenib and doxycycline and the 4th
group did not receive any further therapy. The therapy group of mice
treated with vemurafenib alone exhibited rapid tumor growth as de-
tected by calipermeasurements and PET imaging (Fig. 5a, b). In compar-
ison, a doxycyclinemediated down-regulation ofβ-catenin signiﬁcantly
decelerated tumor growth compared to continuous BRAFi therapy. A re-
duced tumor growth after knockdown of β-catenin could be also ob-
served in the group that did not receive further vemurafenib
injections (Fig. 5a). Immunohistochemistry staining of isolated tumors
from double treated mice indicated a clearly decreased protein expres-
sion of the proliferation marker Ki67 and phospho-ERK1/2 in compari-
son to the other therapy groups, conﬁrming the reduced tumor cell
growth (Fig. 5c, d) and the previous in vitro data. Analysis of the time
points when the abort criteria were reached showed a survival beneﬁt
formice receiving combinatorial therapy of BRAFi and β-catenin knock-
down. None of these double-treated mice reached the maximum toler-
able tumor size (15 mm in diameter) within the observation time of
40 days, in contrast to the mice of the control and single treated groups
(Supplementary Fig. 3d).
3.3. β-Catenin Acts Independent of the TCF/LEF Dependent Canonical Wnt-
Signaling in the Resistance Mechanism Towards Vemurafenib Treatment
Since nuclear accumulation of β-catenin is strongly indicative for its
transcriptional activity in the canonical Wnt signaling pathway, we an-
alyzed the impact of nuclearβ-catenin on TCF/LEF dependent gene tran-
scription in BRAFi resistant cells. Therefore, TCF/LEF dependent
transcription was determined using a luciferase reporter assay
(Super8xTOPFlash) in vemurafenib sensitive and resistant Mel1617,
451Lu and A375 melanoma cell lines (Fig. 6a). Since the three resistant
cell lines exhibit increased nuclear accumulation of β-catenin, we ex-
pected to ﬁnd an increase in luciferase activity in resistant clones versus
their sensitive counterparts. Surprisingly, the basal level of the TCF/LEF
dependent signal was not clearly induced in resistant cells and even re-
duced in the 451Lu-R cells compared to the sensitive parentals (Fig. 6a).
Stabilization of β-catenin using lithium chloride (15 mM) resulted in a
markedly increased TOPFlash luciferase signal in resistant and sensitive
cells but revealed a signiﬁcantly diminished induction factor of TCF/LEF
dependent gene transcription in the resistant cells. A lower TOPFlash lu-
ciferase signal is suggestive for reduced interaction of β-catenin with
TCF/LEF. Thereforewe performed co-immunoprecipitation experiments
of β-catenin in 451Lu, Mel1617 and A375 cells with subsequent immu-
noblotting for microphtalmia-associated transcription factor (Mitf),
Lymphoid enhancer-binding factor 1 (LEF-1) or T-Cell-Speciﬁc Tran-
scription Factors (TCF). All three are known to be important interactants
of nuclear β-catenin inmelanocytic cells. In the BRAFi resistant melano-
ma cell lines the interaction with LEF-1, TCF-4 and Mitf was at very
weak levels, conﬁrming that the additional amount of nuclear β-
catenin is not mainly involved in the canonical Wnt signaling pathway
in these cells. Of note the expression of TCF-4 and LEF-1 as well as of
Mitf was diminished in the resistant cell lines Mel1617-R and 451Lu-R
compared to the sensitive parentals (Fig. 6b). In a GST-pulldown assay
employing GST-tagged TCF-4 we also found a rather signiﬁcantly re-
duced interaction capacity of β-catenin with TCF-4 in resistant versus
sensitive melanoma cells (451Lu and Mel1617) conﬁrming that the in-
creased nuclearβ-catenin levels in the resistant cells do not increase the
canonical Wnt signaling capacity (Supplementary Fig. 4a). This was in
line with the analysis of previously published transcriptome data on
ﬁfty-nine melanomas from twenty-one different patients before chron-
ic therapy with a BRAFi and after resistance had developed (Rizos et al.,
2014). Transcriptome analysis using gene sets related to the regulation
of nuclear β-catenin signaling and target gene transcription did not re-
veal a differential expression of the β-catenin interaction partners LEF1
or TCF7L2 (TCF-4) (Supplementary Fig. 4b).
Furthermore, we inhibited protein interactions of β-catenin with
TCF/LEF by the treatment with sub-toxic concentrations of the β-
catenin antagonist PKF115–584 (Sinnberg et al., 2011). Surprisingly,
similar to the β-catenin stabilization by lithium chloride, the inhibition
of the interaction between β-catenin and TCF/LEF factors enhanced the
resistance towards vemurafenib in the sensitive 451Lu cell line which
indicates a β-catenin mediated TCF/LEF independent resistancemecha-
nism by the release of β-catenin from this complex. The degree of resis-
tance remained unaltered in the corresponding resistance-acquired cell
line using PKF115–584 (Fig. 6c). We further used the Super8xTopFlash
reporter to analyze the effect of BRAFi on the TCF-4/LEF-1 dependent
transcriptional activity of β-catenin. We therefore treated sensitive
and resistant cells that had been transfectedwith the reporter construct
with increasing concentrations of vemurafenib for 24 h using clinically
relevant doses of 1–10 μM. BRAFi treatment reduced the luciferase sig-
nal in the sensitive cells in a signiﬁcant and concentration-dependent
manner. This effect was less pronounced in the resistant cell lines
(Fig. 6d). This was in agreement with a rather low binding capacity of
β-catenin to TCF-4 after treatment with vemurafenib in a pulldown
assay (Supplementary Fig. 4a). Finally, to evaluate a potential direct ef-
fect of Wnt ligands that activate either the canonical Wnt or non-
canonical Wnt/Ca2+ signaling pathways on vemurafenib resistance,
we treated the sensitive melanoma cell lines 30min before the addition
of vemurafenib with Wnt3a or Wnt5a. Both pre-treatments did not
change sensitivity towards the BRAFi in the cells (Supplementary
Fig. 4c, d). In order to further illuminate a possible role of the non-
canonicalWnt pathways in our resistant cell lineswe used luciferase re-
porter assays (Ring et al., 2014) detecting transcriptional activity of pro-
tein kinase A (PKA) signaling (CRE/cAMP responsive element binding
sites), Ca2+/protein kinase C (PKC) signaling (NFAT/nuclear factor of ac-
tivated T cells binding sites) and jun N-terminal kinase (JNK) signaling
(AP-1/activator protein 1 binding sites). No signiﬁcant correlation be-
tween β-catenin expression and reporter activity was seen. Interesting-
ly, resistant cells showed a lower basal non-canonical Wnt activity than
Fig. 7. Interaction of β-catenin with Stat3 occurs preferentially in BRAFi resistant melanoma cells. a) Co-immunoprecipitation experiments were done to conﬁrm an interaction of β-
catenin with Stat3. Lysates were prepared after crosslinking of the proteins with 0.4% buffered formaldehyde using the sensitive and resistant versions of 451Lu and Mel1617 cells.
Precipitation was performed with a β-catenin or a Stat3 speciﬁc antibody and detected by immunoblot. Semi-quantiﬁcation by densitometric analysis was done by calculating the
ratios (bound fraction:input fraction) followed by normalization to the sensitive cells (see numbers below the blots and table). b) Immunoblot analysis for Stat3 expression and
phosphorylation (Ser727 and Tyr705) in the sensitive and resistant 451Lu, Mel1617 and A375 cell lines. The same lysates as in Fig. 1B were used. Beta-actin protein levels served as
loading controls. c) Fireﬂy reporter assay for Stat3 speciﬁc transciption was used to detect the nuclear Stat3 signaling activity in the sensitive and resistant melanoma cells of 451Lu,
Mel1617 and A375. LiCl (15 mM for 24 h) treatment was used to induce β-catenin accumulation. Fireﬂy signals were normalized to CMV-renilla control signals. Mean values +/− SD
of sixtuplicates are shown.Multiple t-tests with Holm–Šídák correctionwere used to compare data of sensitive and resistant samples and p b 0.05was considered as signiﬁcant (asterisk).
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sensitive parental cells. This activitywas reduced after stabilization ofβ-
catenin with LiCl in sensitive 451Lu and Mel1617 cells but not in resis-
tant cells (Supplementary Fig. 4e). Together, these data strongly support
the hypothesis that stabilized nuclearβ-catenin acts at least partially in-
dependent of the common TCF-4/LEF-1 dependent canonical Wnt/β-
catenin signaling in the mediation of vemurafenib resistance.
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3.4. Stat3 Signaling Is Critical for the β-Catenin Mediated Resistance To-
wards Vemurafenib
Since we found that resistance mediation of β-catenin to BRAFi is
largely independent of the canonical Wnt signaling in melanoma cells
we investigated the involvement of other factors. Therefore, we
performed co-immunoprecipitation of β-catenin in nuclear extracts of
sensitive and resistant Mel1617 cells followed by LC-MS/MS analyses
of the interaction partners (Supplementary Table 1). Among the top
candidates of identiﬁed nuclear proteins enriched in the Mel1617-R
sample, Stat3 was suspicious as a critical β-catenin interaction with a
signiﬁcantly increased interaction in resistant compared to sensitive
cells (Supplementary Fig. 5a, Supplementary Table 2). We further per-
formed an in silico analysis of the interactome of β-catenin and Stat3
and found a set of 148 shared interactants including β-catenin and
Stat3 itself (Supplementary Fig. 5b). We conﬁrmed the increased inter-
action of β-catenin with Stat3 in resistant compared to sensitive 451Lu
and Mel1617 cells by western blot analysis after immunoprecipitation
of either of the interaction partners. The interaction could be detected
in both directions by using antibodies speciﬁc for β-catenin or Stat3
for the precipitation and the reciprocal antibody for immune-
detection with increased occurrence in resistant 451Lu and Mel1617
cells (Fig. 7a). In A375-R cells we also found increased amounts of β-
catenin in the anti-Stat3 precipitates conﬁrming the increased interac-
tion in BRAFi resistant cells. In SKMel19-R cells the interaction could
be detected but was not increased when compared to SKMel19-S cells
(Fig. 7a). Stat1 could not be detected in immunoprecipitations of
451Lu and Mel1617 lysates using a β-catenin speciﬁc antibody (data
not shown). In the BRAFi resistant melanoma cell lines 451Lu-R,
Mel1617-R and A375-R that comprised the observed nuclear β-
catenin stabilization and interaction with Stat3, we found increased
phosphorylation of Stat3 at Ser727 and for 451Lu-R additionally at
Tyr705 whereas total Stat3 protein levels were not consistently in-
creased in the lysates (Fig. 7b). Both phosphorylation sites are strong in-
dicators of activated Stat3 signaling. Interestingly, the phospho-Ser727
correlated with β-catenin and phospho-Erk1/2 levels (Fig. 1b & 7b). In-
deed, Stat3 signaling activitywas signiﬁcantly increased in 451Lu-R and
A375-R cells as measured by a Stat3 reporter assay (Fig. 7c) and in
Mel1617-R a non-signiﬁcant trend to increased reporter activity was
measured. Resistant cell lines had higher transcript levels of IL-6
which is a target of Stat3 signaling and at the same time activates
Stat3 via binding to IL6Rα and gp130 activation ending up in a
feedforward loop that further activates Stat3 in the tumor microenvi-
ronment (Supplementary Fig. 1e). Stabilization of β-catenin using LiCl
increased the Stat3 reporter activity in sensitive 451Lu and Mel1617
cells to levels of the corresponding resistant cells (Fig. 7c).
To reveal the functional role of Stat3 in the vemurafenib resistance
mechanisms, we overexpressed Stat3 via lentiviral gene transfer in sen-
sitive A375 and SKMel19 cell lines. As expected the increased
expression of Stat3 resulted in a decreased sensitivity towards
vemurafenib treatment (Fig. 8a). Furthermore, treatment with two dif-
ferent inhibitors of Stat3 activation, S3I-201 (Supplementary Fig. 6a)
and Stattic (Fig. 8b), sensitized the resistance-acquired 451Lu-R,
Mel1617-R and to a lesser extent A375-R and SKMel19-R cells towards
vemurafenib treatment, yielding in a signiﬁcantly reduced IC50 in the
combination treatment of vemurafenib with Stattic compared to the
mono-treatment with vemurafenib (Fig. 8b). Isobologram analysis evi-
denced the synergistic character of combined inhibition of Stat3 and
BRAFV600E in terms of reduced viability in the Mel1617-R and 451Lu-
R BRAFi resistant cells (Supplementary Fig. 6a). In order to test this com-
bination in a more clinical model we used short term cultured melano-
ma cells (three models isolated from patient biopsies and one model
from a patient derived xenograft mouse) whichwere derived from clin-
ically BRAFi-resistant BRAFV600Emelanomas. A similar beneﬁcial effect
of the combination could be measured after three days of treatment in
the viability assay (Fig. 8b).
The sensitizing effect was conﬁrmed by using siRNA against Stat3
combined with vemurafenib treatment in 451Lu-R, Mel1617-R and
A375-R cells. The amount of re-sensitization was comparable to a siRNA
speciﬁc for β-catenin (Fig. 8c). These results were additionally substanti-
atedwith the results obtained using the Tet-inducible shCTNNB1 in com-
bination with the Stat3 inhibitor Stattic or vemurafenib (Fig. 8d,
Supplementary Fig. 6b). To analyze the role of Stat3 and β-catenin inter-
action in vemurafenib sensitivity, we treated the Tet-inducible shCTNNB1
451Lu-R cells with Stattic and vemurafenib in a ﬁxed ratio (3:20) and ad-
ditionally induced a β-catenin knockdown in these cells by a preceding
doxyxcycline addition. The knockdown enabled a signiﬁcant decline of
cell viability at lower concentrations of Stattic and vemurafenib in com-
parison to the control cells without the induction of shCTNNB1. As before,
β-catenin down-regulation reduced vemurafenib resistance and lowered
the IC50 for vemurafenib 3.7 fold and the IC50 of Stattic approx. 1.3 fold. In
combination with the double treatment (using vemurafenib plus Stattic)
the induced shRNA acted in an additive to superadditive manner in the
resistance-acquired 451Lu-Tet cells (Fig. 8d). These data strongly support
an important role of β-catenin for the Stat3 mediated resistance towards
vemurafenib.
4. Discussion
Acquired resistance to the second generation BRAF inhibitor
vemurafenib is limiting the beneﬁts of long term targeted therapy for
patients withmalignantmelanomas that harbor the V600E BRAFmuta-
tion (Chapman, 2013; Wagle et al., 2011). Recent studies revealed an
enormous heterogeneity of underlying resistant mechanisms within
the individual patients but also within single tumors (Hoogstraat
et al., 2014; Rizos et al., 2014; Shi et al., 2014). The selective pressure
of BRAFi can force clonal evolution of a variety of different phenotypes.
This heterogeneity is at least partly reﬂected in our cell line models of
Fig. 8. Stat3 and β-catenin levels cooperatively mediate resistance to BRAFi in melanoma cells. a) Stat3 was overexpressed in sensitive A375 and SKMel19 cells using a lentivirus (LV-
STAT3). After selection the stable overexpression was tested by western blot and the cells were used for cell viability testings (MUH) after 72 h of treatment with vemurafenib. Signals
were normalized to the control cells without vemurafenib treatment. Mean +/− SD values of six replicates are shown. Multiple t-tests with Holm–Šídák correction were used to
compare data points of the two curves and p b 0.05 was considered as signiﬁcant (asterisk). F-test revealed a signiﬁcant different IC50 of the ﬁtted curves. b) Cell viability (MUH assay)
72 h after combinatorial inhibition of Stat3 by Stattic and BRAFV600E by vemurafenib in resistant Mel1617-R, 451Lu-R, A375-R and SKMel19-R cells (top row). Stattic and
vemurafenib were mixed in a ﬁxed ratio (3:20) with the maximum concentrations 3 μM for Stattic and 20 μM for vemurafenib. Cells were treated with the inhibitors in ascending
concentrations of the combined drugs. 72 h after treatment cell viablitiy was assessed in quintuplicates. The top x-axes represent the concentrations of Stattic and the bottom x-axes
represent the concentrations of vemurafenib. Mean +/− SD values are shown. Multiple t-tests with Holm–Šídák correction were used to compare data points of the curves and
p b 0.05 was considered as signiﬁcant (asterisk). F-test revealed a signiﬁcant different IC50 of the ﬁtted curves. Four short-term melanoma cultures from clinically BRAFi resistant
tumors were used for viability testing at 72 h after beginning with either mono or combinatorial treatment using Stattic and vemurafenib (bottom row). c) Cell viability after
knockdown of β-catenin. siRNA (50 nM) was used to speciﬁcally downregulate either β-catenin or Stat3 in the resistant 451Lu-R, Mel1617-R and A375-R cells. 24 h post transfection
cells were treated with increasing concentrations of vemurafenib for 72 h before the measurement of cell viability via MUH assay. Each assay was performed in quintuplicates.
Multiple t-tests with Holm–Šídák correction were used to compare data points of the curves and p b 0.05 was considered as signiﬁcant (asterisk). d) The 451Lu-TetOn-shCTNNB1
resistant cells were used for double (left and middle diagram) and triple targeting (right diagram) of β-catenin (using doxycycline), Stat3 (using Stattic) and BRAFV600E (using
vemurafenib). For the knockdown of β-catenin cells were pretreated with 1 μg/ml doxycycline before the addition of the inhibitors. After 72 h of treatment cell viability was assessed.
Multiple t-tests with Holm–Šídák correction were used to compare data points of the curves and p b 0.05 was considered as signiﬁcant (asterisk). Knockdown of β-catenin reduced
the IC50 of vemurafenib 3.7fold and the IC50 of Stattic 1.3fold. Combination of the knockdown with both inhibitors resulted in an additive effect as shown in the isobologram.
Intersections with the axes denote the IC50 values of the corresponding inhibitors. The measured effective IC50 of the combinations are depicted by the dots. Data points of the assay
with knockdown are shown in red, black data points represent the cells without knockdown of β-catenin.
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resistance where we have diverse expression levels of RTKs and differ-
ent effects on the level of BRAF that cause the reactivation of the
MAPK signaling pathway under vemurafenib treatment. This demon-
strates the need to identify common signaling nodes which merge sev-
eral resistance mechanisms and could be used as additional target
structures like the recent discovery of the translational regulator com-
plex EIF4F (Boussemart et al., 2014) or Pax3/Mitf during the adaptation
phase to BRAFi (Smith et al., 2016).
Our present results provide additional insight into the complexity of
the vemurafenib resistance phenotype of melanomas and advance the
basis uponwhich such resistancemay be overcome. The ﬁrst major ﬁnd-
ing in this work is the increase of β-catenin protein levels in about half of
the melanoma metastases with acquired resistance towards
vemurafenib. This suggests that β-catenin plays a role in a subset of mel-
anoma cells with acquired resistance towards BRAFi. In line with the de-
scribed heterogeneity of resistant melanomas this subset would be
ideally suitable for β-catenin targeting. We clearly show that reduced
β-catenin levels can strongly enhance the growth inhibitory and apopto-
tic effects of vemurafenib in a synergistic manner in these cells. More-
over, knocking down of β-catenin levels partially re-sensitized our
resistant melanoma cell lines for the BRAF inhibitor vemurafenib. This
demonstrates that an increasedβ-catenin protein levelmediates survival
of melanoma cells during a therapy resistant state which is in line with a
recentﬁnding of Chien et al. (Chien et al., 2014), showing aworse surviv-
al of BRAFi treated patients with melanomas containing the BRAFV600E
mutation and high β-catenin levels compared to patients with tumors
having low β-catenin levels. This supports our previous studies demon-
strating that β-catenin can positively affect melanoma cell survival
(Sinnberg et al., 2010, 2011). Moreover, we show that knocking down
of β-catenin delays the development of resistance to vemurafenib
under chronic BRAF inhibition, which further strengthens the important
role of β-catenin in the formation of acquired resistance to BRAF inhibi-
tors in melanoma. In the light of the role of Mitf during the adaptation of
melanoma cells to BRAFi (Smith et al., 2016) this makes perfect sense
since it is known that β-catenin regulates the expression of Mitf
(Widlund et al., 2002). However enhanced β-catenin signaling seems
not to be generally protective in BRAF mutated melanoma cell lines.
Chien and Moon showed enhanced apoptosis induction in some cell
lines showing an activated Wnt-/β-catenin signaling after BRAF inhibi-
tion (Biechele et al., 2012) as well as after MEK inhibition (Conrad
et al., 2012). However, their results suggest that in melanoma cells ex-
posed to long-term BRAFi, the transcriptional effects of Wnt/β-catenin
signaling (measured by AXIN2 transcript levels) are uncoupled from
the enhancement of apoptosis by Wnt/β-catenin signaling. A very early
activation of the canonical Wnt signaling pathway after 3–6 h of BRAFi
treatment could be detected in our cell lines, too (data not shown)
which declined below starting levels after 24 h of BRAF inhibition.
In our resistant melanoma cells the elevated levels of β-catenin did
not cause an increase in activity of the canonical Wnt signaling pathway
although the increase in β-cateninwas also detectable on a nuclear level.
Target gene expression like MITF (Dorsky et al., 2000; Widlund et al.,
2002) and Tyrosinase (Wang et al., 2015) was even reduced in the resis-
tant cells. This is in accordancewith a previously identiﬁed resistant sub-
population of chronically treated melanomas with low MITF expression
(Müller et al., 2014). Similar resultswere seen by Chien et al. after chron-
ic treatment of cells with PLX4027 that did not cause increased canonical
Wnt signaling activity (Chien et al., 2014). Beyond that, activation ofWnt
signaling by Wnt3a stimulation did not mediate resistance to our
melanoma cells tested and also did not further sensitize the cells to
vemurafenib treatment. In contrast, stabilization of β-catenin by lithium
chloride aswell as the liberation ofβ-catenin fromcomplexeswith TCF4/
LEF1 by treatmentwith PKF115–584 reducedmelanoma susceptibility to
the BRAF inhibitor vemurafenib. This hints at a Wnt signaling indepen-
dent function of β-catenin in the course of resistance to BRAF inhibition.
Beta-catenin can be also stabilized by non-canonical Wnt ligands like
Wnt5a, dependent on the receptor context. While binding of Wnt5a to
Ror2 usually inhibits the canonical β-catenin dependent signaling path-
way (van Amerongen et al., 2012), its binding to frizzled 4/Lrp6 is known
to stabilize β-catenin (Grossmann et al., 2013; Mikels and Nusse, 2006).
The non-canonical signaling ofWnt5a including the downstream activa-
tion of PKC is known to be activated in highly invasive melanomas
(Dissanayake et al., 2007; Hoek et al., 2008; Weeraratna et al., 2002).
MoreoverWnt5awas previously found tomediate intrinsic and acquired
therapy resistance of melanoma cells to BRAFi by signaling through Ror2
(O'Connell et al., 2013). In another recent work Wnt5a expression was
shown to be increased in a subset of melanoma cells with activation of
Akt mediating acquired resistance to BRAFi (Anastas et al., 2014). Inter-
estingly, the receptors frizzled-7 and Ryk were suspected of mediating
this effect. In xenopus cells frizzled-7 is also capable to activate β-
catenin after binding of Wnt5a (Umbhauer et al., 2000), which could
be a hint on Wnt5a dependent β-catenin stabilization in therapy resis-
tant melanoma cells. However, although the resistant form of Mel1617
showed increased expression of Wnt5a no tendency towards increased
Wnt5a levels was detected in the other resistant cells tested. In addition,
Wnt5a stimulation of sensitive melanoma cell lines did not signiﬁcantly
attenuate the efﬁcacy of vemurafenib. Thereby, we exclude a Wnt3a or
Wnt5a dependent stabilization of β-catenin in our cell lines with ac-
quired resistance and we further reason that β-catenin has a Wnt inde-
pendent function in the acquired resistance mechanisms to BRAFi.
From previous studies it is known that the interaction partners of β-
catenin seem to dictate its functional activities. In melanoma cells inter-
action of β-catenin with TCF4 drives invasivemelanoma growth, where-
as interaction with LEF1 predominated in a proliferative phenotype
(Eichhoff et al., 2011).
Indeed the second major ﬁnding of our work is a so far non-
described interaction of β-catenin with the signal transducer and
activator of transcription 3 (Stat3) in resistant melanoma cells. Our
data prove for the ﬁrst time a physical interaction of the transcription
factors β-catenin and Stat3. The levels of β-catenin in melanoma cells
seem to change the signaling activity of Stat3 as determined by β-
catenin stabilization. This hints on a regulatory function of β-catenin
protein levels in Stat3 signaling. In cutaneous melanoma, activation of
Stat3 signaling is known to be a negative prognostic factor (Lee et al.,
2012; Wang et al., 2007). Our observation that Stat3 overexpression
increases vemurafenib resistance and Stat3 knockdown or inhibition in-
creases sensitivity towards vemurafenib is in coincidence with a recent
study showing an important role of Stat3 signaling in the mediation of
resistance to BRAFi by the induction of the transcription factor Pax3
(Liu et al., 2013). In addition, we found an increase of Stat3 phosphory-
lation at Ser727 in the same cell lines that showed increased nuclear
levels of β-catenin. Phosphorylation at Tyr705 was more variable in
the resistant cells conﬁrming the ﬁnding that phosphorylation of
Ser727 can occur independently of Tyr705 in melanocytic cells
(Sakaguchi et al., 2012). Furthermore Stattic reduced melanoma cell
viability together with vemurafenib in a synergistic manner in BRAFi
resistant melanoma cell lines and patient derived short-term cultures.
Additional knockdown of β-catenin further enhanced this growth
inhibitory effect. Interestingly, beyond the direct interaction, Stat3 and
β-catenin share interaction partners that are known to be involved in
the re-activation of MAPK signaling pathways or the hyperactivation
of PI3K/Akt signaling during the acquisition of resistance to BRAFi.
Among those are the receptor tyrosine kinases Erbb2/3 and c-Met,
that mediate resistance via ligand dependent activation of down-
stream signaling adaptor molecules like Src which is also among the
common interactants. Nrg-1, a ligand of Erbb2/Erbb3 Egf-receptor
complexes was shown to mediate resistance in melanoma cells to
BRAFi (Abel et al., 2013; Tiwary et al., 2014; Wilson et al., 2012) as
well as Hgf, the ligand of c-Met (Straussman et al., 2012; Wilson et al.,
2012). In malignant melanoma these growth factors can be expressed
by stromal cells like cancer associated ﬁbroblasts (Straussman et al.,
2012). The corresponding receptors are capable to activate β-catenin
upon ligand binding. A putative mechanism could be the activation of
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members of the Src kinase family. Interestingly, BRAF and MEK inhibi-
tion can directly cause an intermediate phosphorylation of Stat3 via
RTK-driven Src activation in a subset of melanomas (Vultur et al.,
2014). A second mechanism of Stat3 activation in the course of resis-
tance acquisition towards BRAFi might be the ﬁnding of increased ex-
pression of IL-6 which activates the Stat3 signaling pathway via its
receptor gp130 homodimerization and janus kinase (JAK) activation.
Again, JAK1 has gained attention in terms of mediation of primary resis-
tance (Sos et al., 2014) and of secondary resistance to BRAFi (Kim et al.,
2015).
Our data indicate that β-catenin and Stat3 are both downstream tar-
gets of important mediators of resistance acquisition against chronic
treatment with BRAFi and converge in a signaling node. During resis-
tance development β-catenin obviously changes its nuclear interaction
partners to Stat3. The convergence of resistance mediating pathways at
the level ofβ-catenin and Stat3 by the formation of a novel protein com-
plex turns this interaction into an important nodal point. According to
our ﬁnding that inhibition of Stat3 and knockdown of β-catenin both
synergized with vemurafenib in the resistant melanoma cells as well
as in their combination, targeting of this signaling complex seems to
be a promising strategy to improve targeted therapies with BRAFi. Fur-
ther investigation is needed to decipher the importance of theβ-catenin
Stat3 interaction for the canonicalWnt pathway, the Stat3 signaling and
the resistance acquisition to MAPK pathway inhibitors like BRAFi and
MEKi. A further in-depth characterization of the activatingmechanisms
of Stat3 might lead to novel therapeutic target structures that are
capable to overcome acquired resistance to BRAF and maybe even
MEK inhibition.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.037.
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